CRISPR Therapeutics
CRSP
CRSP
174 hedge funds and large institutions have $1.09B invested in CRISPR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
174
Holders Change
+39
Holders Change %
+28.89%
% of All Funds
3.99%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
70
Increased
52
Reduced
32
Closed
30
Calls
$29.7M
Puts
$86.8M
Net Calls
-$57.1M
Net Calls Change
-$35.1M
Top Buyers
| 1 |
1
Federated Hermes
Pittsburgh,
Pennsylvania
|
$37.1M |
| 2 |
AIM
2
ARK Investment Management
St. Petersburg,
Florida
|
$27.4M |
| 3 |
O
3
OrbiMed
New York
|
$29.2M |
| 4 |
4
Two Sigma Advisers
New York
|
$21.7M |
| 5 |
5
Lord, Abbett & Co
Jersey City,
New Jersey
|
$13.3M |
